State Street SPDR S&P Biotech ETF
713 hedge funds and large institutions have $7.22B invested in State Street SPDR S&P Biotech ETF in 2023 Q2 according to their latest regulatory filings, with 72 funds opening new positions, 185 increasing their positions, 273 reducing their positions, and 67 closing their positions.
1.39% more ownership
Funds ownership: 110.75% → 112.14% (+1.4%)
7% more first-time investments, than exits
New positions opened: 72 | Existing positions closed: 67
0% more funds holding
Funds holding: 713 → 713 (0)
0% less capital invested
Capital invested by funds: $7.23B → $7.22B (-$13.1M)
17% less funds holding in top 10
Funds holding in top 10: 23 → 19 (-4)
32% less repeat investments, than reductions
Existing positions increased: 185 | Existing positions reduced: 273
36% less call options, than puts
Call options by funds: $1.15B | Put options by funds: $1.8B
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Goldman Sachs
New York
|
+$434M |
| 2 |
BNP Paribas Financial Markets
Paris,
France
|
+$137M |
| 3 |
SG Americas Securities
New York
|
+$47.4M |
| 4 |
Jane Street
New York
|
+$29.1M |
| 5 |
State of Wisconsin Investment Board
Madison,
Wisconsin
|
+$26.1M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Barclays
London,
United Kingdom
|
-$240M |
| 2 |
JP Morgan Chase
New York
|
-$205M |
| 3 |
Two Sigma Advisers
New York
|
-$143M |
| 4 |
Bank of America
Charlotte,
North Carolina
|
-$143M |
| 5 |
Citigroup
New York
|
-$118M |
XBI Hedge Fund Activity: Q2 2023 in Review
713 of the 6,369 institutional investors tracked by Wall St. Rank reported a position in State Street SPDR S&P Biotech ETF (XBI) for Q2 2023, worth a combined $7.22B — down 0.18% from $7.23B a quarter earlier.
Buyers outnumbered sellers: 72 funds opened new XBI positions and 67 closed out — a net gain of 5 holders — while 185 added to existing stakes and 273 trimmed.
The largest buyer was Goldman Sachs, adding an estimated $434M. The largest seller was Barclays, cutting an estimated $240M.
- 713 institutional investors held State Street SPDR S&P Biotech ETF (XBI) as of Q2 2023, unchanged from Q1 2023.
- Funds reported $7.22B of State Street SPDR S&P Biotech ETF stock for Q2 2023, down 0.18% quarter-over-quarter.
- 72 funds opened new State Street SPDR S&P Biotech ETF positions in Q2 2023 and 67 closed out, a net change of +5 holders.
- The largest State Street SPDR S&P Biotech ETF buyer in Q2 2023 was Goldman Sachs, an estimated $434M added.
- The largest State Street SPDR S&P Biotech ETF seller in Q2 2023 was Barclays, an estimated $240M sold.
Based on aggregated 13F filings for Q2 2023.